Switzerland · Delayed Price · Currency is CHF Ypsomed Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Achieved record sales and EBIT, driven by strong growth in Delivery Systems and successful transformation into a focused, high-margin business. Outlook remains robust with double-digit sales growth and margin targets, supported by innovation, operational excellence, and global expansion.
-
Management outlined a strategic shift to a pure-play injection device business, driven by strong growth in injectables, biosimilars, and GLP-1 therapies. Financial targets include doubling sales by 2030, maintaining high margins, and expanding global production, with risks mainly in execution and market volatility.
-
Core Delivery Systems sales rose 21% year-over-year, with EBIT margin at 32.4% and strong cash flow supporting major global capacity expansion. Auto-injector sales surged 46%, while pens were flat; guidance for 20% annual growth and >30% EBIT margin is reaffirmed.
Fiscal Year 2025
-
Exceeded financial targets with 37% sales growth and strong EBIT, driven by auto-injectors and global expansion. Transitioned to a pure play delivery systems specialist, divested non-core businesses, and guided for 20% growth and higher profitability next year.
-
A CHF 420 million deal to divest the Diabetes Care business to TecMed AG will transform the company into a pure-play injection system specialist, with proceeds funding core business expansion and no special dividend planned. The transaction includes an earn-out tied to sales, continued contract manufacturing, and significant operational shifts in Solothurn and Burgdorf.
-
Strong revenue and EBIT growth driven by delivery systems and diabetes care, with continued global expansion and a solid balance sheet. Strategic divestments and a robust project pipeline support a positive outlook, with guidance reaffirmed for 25% top-line growth and CHF 140 million EBIT.